Literature DB >> 6304206

Infections due to herpesviruses in cardiac transplant recipients: role of the donor heart and immunosuppressive therapy.

J K Preiksaitis, S Rosno, C Grumet, T C Merigan.   

Abstract

The role of the donor heart and immunosuppressive therapy on infection due to herpesviruses in 74 cardiac transplant recipients (CTRs) was determined. When cellular blood products from donors seronegative for antibody to cytomegalovirus (anti-CMV) were used, all primary CMV infections were attributable to transmission from donor heart. None of eight CTRs negative for anti-CMV before transplant and who received an anti-CMV donor heart and anti-CMV blood products developed CMV infection compared to one (20%) of five who received unscreened blood. A change from high-dosage anti-thymocyte globulin, azothioprine, and prednisone (ATG regimen) to low-dosage anti-thymocyte globulin, cyclosporin A, and prednisone (CsA regimen) significantly decreased the severity and prevalence of lesions due to herpes simplex virus and the duration of CMV shedding in patients with recurrent CMV infection. CTRs with recurrent CMV infection treated with the ATG regimen had significantly more fever, required more parenteral antibiotics, and were more likely to be infected with opportunistic pathogens than were CsA-treated patients.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6304206     DOI: 10.1093/infdis/147.6.974

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  15 in total

1.  Cardiac Transplantation: Pre-transplant Infectious Diseases Evaluation and Post-transplant Prophylaxis.

Authors:  Susan Keay
Journal:  Curr Infect Dis Rep       Date:  2002-08       Impact factor: 3.725

2.  Demonstration of cytomegalovirus nucleic acids in the coronary arteries of transplanted hearts.

Authors:  T C Wu; R H Hruban; R F Ambinder; M Pizzorno; D E Cameron; W A Baumgartner; B A Reitz; G S Hayward; G M Hutchins
Journal:  Am J Pathol       Date:  1992-03       Impact factor: 4.307

3.  Decreased incidence of viral infections in liver transplant recipients. Possible effects of FK506?

Authors:  N Singh; L Mieles; V L Yu; T E Starzl
Journal:  Dig Dis Sci       Date:  1994-01       Impact factor: 3.199

4.  The effects of cyclosporin A on the induction, expression and regulation of the immune response to herpes simplex virus.

Authors:  D M Altmann; W A Blyth
Journal:  Clin Exp Immunol       Date:  1985-01       Impact factor: 4.330

5.  Detection of cytomegalovirus antibody with two commercially available assays, an indirect hemagglutination test and an enzyme immunosorbent assay.

Authors:  S H Cheeseman; G V Doern; R A Ferriani; M W Keville; B R McGraw; J A Stewart
Journal:  J Clin Microbiol       Date:  1984-07       Impact factor: 5.948

6.  Non-radioactive in situ hybridization for the detection of cytomegalovirus infections.

Authors:  A K Raap; J L Geelen; J W van der Meer; F M van de Rijke; P van den Boogaart; M van der Ploeg
Journal:  Histochemistry       Date:  1988

7.  OKT3 and viral disease in pediatric liver transplant recipients.

Authors:  James S Bowman; Michael Green; Velma P Scantlebury; Saturo Todo; Andreas Tzakis; Shunzaburo Iwatsuki; Laura Douglas; Thomas E Starzl
Journal:  Clin Transplant       Date:  1991-08       Impact factor: 2.863

8.  Rapid detection of cytomegalovirus in clinical specimens by using biotinylated DNA probes and analysis of cross-reactivity with herpes simplex virus.

Authors:  N S Lurain; K D Thompson; S K Farrand
Journal:  J Clin Microbiol       Date:  1986-11       Impact factor: 5.948

9.  Definition of a subset of human peripheral blood mononuclear cells that are permissive to human cytomegalovirus infection.

Authors:  C Söderberg; S Larsson; S Bergstedt-Lindqvist; E Möller
Journal:  J Virol       Date:  1993-06       Impact factor: 5.103

10.  Passive immunization against cytomegalovirus in allograft recipients. The Rotterdam Heart Transplant Program experience.

Authors:  A H Balk; W Weimar; P H Rothbarth; K Meeter; H J Metselaar; B Mochtar; M L Simoons
Journal:  Infection       Date:  1993 Jul-Aug       Impact factor: 3.553

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.